These findings suggested that selective activation of the WDR5-MHC I pathway and/or selective inhibition of the WDR5–immune checkpoint/cytokine pathways should be taken into consideration in WDR5-based epigenetic cancer immunotherapy. This evidence concerns the gene WDR5 and cancer.